BioCardia, Inc.
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
About BioCardia
Biological Products, (No Diagnostic Substances), SIC 2836
BioCardia, Inc. is a clinical-stage biotechnology company that develops cellular and cell-derived therapeutics to treat cardiovascular and pulmonary conditions. The company's pipeline includes the CardiAMP autologous mononuclear cell therapy platform, which targets ischemic heart failure with reduced ejection fraction and refractory angina from chronic myocardial ischemia. It also develops an allogeneic mesenchymal stem cell platform for heart failure and acute respiratory distress syndrome. In addition, the company produces the Helix transendocardial biotherapeutic delivery system, a catheter-based platform for delivering therapies into heart tissue. BioCardia serves patients suffering from severe cardiac diseases and collaborates with biopharmaceutical partners by providing delivery systems and specialized development services.
The company operates corporate headquarters and laboratory facilities in Sunnyvale, California. Its clinical development and regulatory activities are based primarily in the United States and Japan.
Summary of the business section of BioCardia's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioCardia, Inc.
- Headquarters
- Sunnyvale, CA
- Address
- 320 Soquel Way 94085
- Phone
- (650) 226-0123
- Website
- biocardia.com
- Employees
- 21, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PKF San Diego, LLP, San Diego, California
Stock & identifiers
- Ticker
- BCDA
- Exchange
- Nasdaq
- IPO date
- Nov 13, 1996
- Shares outstanding
- 15M, Aug 11, 2026
- Public float
- $9.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, May 30, 2024; 1-for-9 reverse, Aug 14, 2019; 1-for-9 reverse, Jun 6, 2019; 1-for-12 reverse, Nov 3, 2017; 1-for-12.33 reverse, Mar 30, 2017; 1-for-10 reverse, Mar 14, 2008; 6-for-1, Jan 6, 2004; 1-for-3 reverse, Aug 23, 2001
- SEC CIK
- 925741
- CUSIP
- 09060U606
- ISIN
- US09060U6064
- LEI
- 5493003EDBXRQRW22O75
- EIN
- 23-2753988
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Peter Altman | President and CEO, Director | 384,885 |
| Edward M. Gillis | Senior Vice President, Devices | 54,126 |
| David McClung | Chief Financial Officer | 114,245 |
| Simon H. Stertzer | Director | 225,542 |
| Jim L. Allen | Director | 109,667 |
| Bill Facteau | Director | 13,123 |
| Jay M. Moyes | Director | 213,276 |
| Marvin Slosman | Director | – |
| Andrew Scott Blank | Director | 636,058 |
| Richard M. Krasno | Director | 16,268 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Peter Altman | $493.39K | $423.48K | $303.37K | $22 | – |
| FY2023 Peter Altman | $862.84K | $600.06K | $450.62K | $32 | – |
| FY2022 Peter Altman | $901.90K | $907.18K | $477.40K | $108 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 17 full-time and four part-time employees, consisting of clinical development, product development, regulatory, manufacturing, quality, finance, administration, ”
Corporate history
Events identified from SEC filings